REPLY
19.9.2023 09:31:27 CEST | Business Wire | Press release
Reply, a global systems integrator and consulting firm and Oracle Cloud Managed Service Provider, has received 4 Oracle Partner awards in recognition of its capabilities to deliver pioneering solutions, drive business value and customers success. The EMEA Cluster Partner Awards, announced at the Oracle EMEA Partner Appreciation Reception during Oracle CloudWorld in Las Vegas, have been awarded to the Reply companies specialized on Oracle technologies; Healthy Reply, Nimbus Reply and Red Reply.
The awards celebrate partners that foster innovation, accelerate business growth and create value to enable success for customers through technology integration and services built on Oracle Cloud Application, Oracle Cloud Infrastructure and Oracle Database technology. The Reply companies, focused on Oracle Cloud Infrastructure solutions and experts in end-to-end Oracle solutions, received the following EMEA Cluster Partner Awards:
- 2023 Customer Success Partner of Year – Europe South Tech / Cloud has been given to Nimbus Reply for the high customer satisfaction they have earned by empowering customers with innovative multi-cloud solutions. These resulted in a reduction of operational costs, an increase in application performance and improvements in system scalability, all while considering critical regulatory requirements.
- 2023 Customer Success Partner of Year – Europe North & East Tech / Cloud has been awarded to Red Reply for their capabilities to increase value to their end customers by streamlining solution implementation and management, improving human capital efficiency, reducing costs, minimizing technical debt, and achieving a measurable return on investment.
- 2023 Business Impact Partner of Year – Europe South Apps / SaaS has been assigned to Healthy Reply for developing exceptional solutions based on Oracle SaaS for the healthcare industry. The solutions developed allow to expedite projects and maximise the benefits of Cloud releases resulting invaluable for clients in managing specific processes and integrating with healthcare national systems.
- 2023 Innovation Partner of Year – Europe North & East Tech / Cloud has been granted to Red Reply for their capabilities to create pioneering solutions that empower customers and support these meeting their business goals and challenges. Red Reply have developed a solution that enables companies to seamlessly migrate their Legacy applications to the Cloud quickly. This rapid migration not only results in immediate cost savings but also enhances the company’s operational efficiency. Additionally, the system allows the transformation of Legacy Applications into Cloud-based Software-as-a-Service (SaaS) through a fully managed service, thus eliminating the need for extensive in-house development resources.
Filippo Rizzante, CTO at Reply, said, “We are delighted to have won these awards that reflect our continuous commitment in delivering cutting-edge Oracle solutions. Our ongoing investments in innovation and research & development, together with the expertise and capabilities of our companies dedicated to Oracle technologies allow us to support our customers better and to get the most from Oracle solutions.”
Reply, Oracle partner since 1997, with its companies dedicated to Oracle technologies, is best in class in Oracle Cloud Computing. With over 1500 certifications Oracle, Reply owns and manages one of the main European centers of competence. Reply is able to combine the full coverage of the entire supply chain, has experience in Oracle application suites, in Oracle technologies and in the main Oracle vertical solutions for the industry.
More information about Reply and Oracle partnership here.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Healthy Reply
Healthy Reply is the Reply Group company specialising in telemedicine, telemonitoring and the continuity of social welfare. Healthy Reply collaborates with public and private healthcare institutions and bodies, clinics and hospitals, social and healthcare facilities, insurance companies and banks, convention centres and enterprises, to design customised services that can guarantee continuous care and assistance. Healthy Reply has established strong competencies in Oracle ERPM Cloud solutions and continue to invest in expanding its offerings across all Oracle SaaS solutions.
Nimbus Reply
Nimbus Reply is the Reply Group company specialising in the delivery of Multi-Cloud solutions for the Health and Public Sector market. Composed of specialists with expertise in several Cloud Service Providers, Nimbus Reply promotes the adoption and evolution of the Cloud paradigm in the Public Sector, supporting end-to-end customers in the Journey to Multi-Cloud, in a Cloud Continuum perspective.
Red Reply
Red Reply is the Reply Group company specialising in Oracle Cloud Infrastructure with a focus on IaaS and PaaS solutions and offers Cloud Strategy and Migration, Application Development, Cloud / Application Management and Operations services. Red Reply is an expert in end-to-end Oracle solutions and one of first Oracle Cloud Managed Service Providers (MSP) in Europe. www.red.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919738958/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom